<DOC>
	<DOC>NCT01838590</DOC>
	<brief_summary>This study is to to evaluate the safety, tolerability, and efficacy of sofosbuvir (SOF) plus ribavirin (RBV) in Egyptian adults with genotype 4 hepatitis C virus (HCV) infection.</brief_summary>
	<brief_title>Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Molecular Mechanisms of Pharmacological Action</mesh_term>
	<criteria>Treatment experienced and na√Øve subjects Chronic genotype 4 HCVinfection Not coinfected with HIV Screening laboratory values within defined thresholds Use of highly effective contraception methods Subject must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments. History of any other clinically significant chronic liver disease Pregnant or nursing female or male with pregnant female partner History of clinicallysignificant illness or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol Excessive alcohol ingestion or significant drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Liver Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Hepatitis, Viral, Human</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Enterovirus Infections</keyword>
	<keyword>Picornaviridae Infections</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Flaviviridae Infections</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Anti-Infective Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Antimetabolites</keyword>
	<keyword>Molecular Mechanisms of Pharmacological Action</keyword>
	<keyword>HCV genotype 4 (GT-4)</keyword>
	<keyword>HCV</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>GS-7977</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Open Label</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>Additional relevant MeSH terms:</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis, Chronic</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C, Chronic</keyword>
</DOC>